Characteristics of the patients from TCGA
The clinical data of 467 patients were downloaded from TCGA database, including age, gender, stage, TMN classification and survival status (Table 1).
Table 1
Clinical characteristics of the 467 LUAD patients downloaded from the TCGA database.
Characteristic | N (%) |
Age (years) | |
≤ 60 | 155 (33.19) |
> 60 | 312 (66.81) |
Gender | |
Female | 254 (54.39) |
Male | 213 (45.61) |
Stage | |
I | 251 (53.75) |
II | 108 (21.13) |
III | 75 (16.06) |
IV | 25 (5.35) |
Not available | 8 (3.71) |
T classification | |
T1 | 162 (34.69) |
T2 | 244 (52.25) |
T3 | 39 (8.35) |
T4 | 19 (4.07) |
TX | 3 (0.64) |
M classification | |
M0 | 314 (67.24) |
M1 | 24 (5.14) |
MX | 125 (26.77) |
Not available | 4 (0.85) |
N classification | |
N0 | 300 (64.24) |
N1 | 87 (18.63) |
N2 | 66 (14.13) |
N3 | 2 (0.43) |
NX | 11 (2.36) |
Not available | 1 (0.21) |
Survival status | |
Death | 158 (33.83) |
Survival | 309 (66.17) |
High Tacc3 Mrna Expression In Luad
Based on Oncomine, GEPIA and UALCAN databases, TACC3 mRNA expression in LUAD was determined, respectively. Levels of TACC3 expression were higher in LUAD tissues, compared to the normal tissues (Fig. 1A-C). The results were further confirmed by TCGA database (p = 2.672e-11, Fig. 1D). In addition, there was a significant difference in TACC3 expression in a paired comparison of LUAD and their adjacent normal tissues (p = 2.343e-15, Fig. 1E). These results suggested that TACC3 was highly expressed in LUAD compared with normal tissues.
Prognostic Potential Of Tacc3 In Luad
The role of TACC3 expression on prognostic potential of LUAD patients was determined by Kaplan-Meier Plotter, GEPIA, UALCAN, and TACG databases. No significant difference was found in disease free survival (DFS) by GEPIA (log rank p = 0.05, HR = 1.4, Fig. 2D). However, high TACC3 mRNA expression was significantly associated with poor OS of LUAD patients in Kaplan-Meier Plotter (Log rank p = 1.7e-07, HR = 1.88; Fig. 2B), UALCAN (p < 0.0001, Fig. 2C), GEPIA (Log rank p = 1e-04, HR = 1.8, Fig. 2E), and TCGA analyzed by R (p = 0.002, Fig. 2F). In addition, high TACC3 mRNA expression was significantly associated with poor FP of LUAD patients in Kaplan-Meier Plotter (Log rank p = 5.3e-05, HR = 1.91; Fig. 2A) These results indicated that TACC3 expression had a large impact on the survival of LUAD patients.
Role Of Tacc3 In Clinical Characteristics Of Luad
To evaluate the role of TACC3 in clinical characteristics of LUAD, the relationship between TACC3 expression and clinicopathological characteristics was determined using Kaplan-Meier plotter. As shown in Table 2, TACC3 mRNA expression was negatively associated with OS in female and male patients (p = 0.0084, p = 9.1e-4, respectively), as well as in smoked LUAD patients (p = 0.008). Obviously, high expression of TACC3 was associated with worse OS in stage 1, 3, AJCC stage T1, stage N0, and M0 patients (p = 9.7e-5, p = 0.023, p = 5.2e-4, p = 0.0035 and p = 7.6e-4, respectively). Meanwhile, TACC3 expression was associated with FP in male, never smoked, and stage 1 LUAD patients (p = 5.1e-4, p = 0.027 and p = 0.0058, respectively). In addition, no significant difference was observed in the relationship between TACC3 expression and PPS of LUAD patients. These results suggested that TACC3 expression mainly affected the OS of LUAD patients.
Table 2
Correlation of TACC3 mRNA expression and clinical prognosis in LUAD with different clinicopathological factors by Kaplan-Meier plotter.
Clinicopathological characteristics | OS | | FP | | PPS |
N | HR (95%CI) | Log rank P | | N | HR (95%CI) | Log rank P | | N | HR (95%CI) | Log rankP |
Gender | | | | | | | | | | | |
Female | 318 | 1.67(1.14–2.46) | 0.0084** | | 235 | 1.52(0.96–2.4) | 0.071 | | 59 | 1.19(0.6–2.38) | 0.62 |
Male | 344 | 1.75(1.25–2.44) | 9.1e-4*** | | 226 | 2.16(1.38–3.37) | 5.1e-4*** | | 125 | 0.72(0.38–1.37) | 0.32 |
Smoking history | | | | | | | | | | | |
Never smoked | 22 | 1.47(0.2-10.89) | 0.7 | | 143 | 2.01(1.07–3.78) | 0.027* | | 41 | 0.62(0.26–1.48) | 0.27 |
Smoked | 246 | 1.91(1.17–3.11) | 0.008** | | 461 | 1.51(0.97–2.33) | 0.064 | | 82 | 0.84(0.47–1.48) | 0.54 |
Stage | | | | | | | | | | | |
1 | 370 | 2.25(1.48–3.42) | 9.7e-5*** | | 283 | 1.99(1.21–3.27) | 0.0058** | | 66 | 1.06(0.53–2.1) | 0.88 |
2 | 105 | 1.62(0.93–2.80) | 0.085 | | 103 | 0.94(0.54–1.64) | 0.84 | | 38 | 0.52(0.23–1.15) | 0.099 |
3 | 24 | 3.54(1.11–11.26) | 0.023* | | 10 | - | - | | 1 | - | - |
4 | 4 | - | - | | 0 | | | | 0 | - | - |
AJCC stage T | | | | | | | | | | | |
1 | 123 | 3.18(1.6–6.32) | 5.2e-4*** | | 47 | 1.56(0.35-7) | 0.56 | | 7 | | |
2 | 105 | 1.62(0.93–2.8) | 0.085 | | 93 | 1.62(0.86–3.06) | 0.13 | | 38 | 0.52(0.23–1.15) | 0.099 |
3 | 4 | - | - | | 2 | - | - | | 1 | - | - |
4 | 0 | - | - | | 0 | - | - | | 0 | - | - |
AJCC stage N | | | | | | | | | | | |
0 | 184 | 2.07(1.26-3,4) | 0.0035** | | 102 | 1.31(0.61–2.84) | 0.49 | | 25 | 0.73(0.27–1.95) | 0.53 |
1 | 44 | 1.15(0.53–2.49) | 0.72 | | 38 | 1.24(0.5–3.06) | 0.65 | | 19 | - | - |
2 | 3 | - | - | | 2 | - | - | | 2 | - | - |
AJCC stage M | | | | | | | | | | | |
0 | 231 | 1.99(1.32–2.99) | 7.6e-4*** | | 142 | 1.73(0.97–3.09) | 0.06 | | 46 | 0.62(0.3–1.28) | 0.19 |
1 | 1 | - | - | | 0 | - | - | | 0 | - | - |
- Sample number too low for meaningful analysis. *p < 0.05, **p < 0.01, ***p < 0.0001. |
Diagnostic Value Of Tacc3 Expression In Luad Patients
To further elucidate the role of TACC3 in diagnostic value in LUAD patients, ROC curves were generated by SPSS26.0. The AUC was 0.940, which suggested that the level of TACC3 mRNA expression was a strong diagnostic value in LUAD (Fig. 3A). In addition, we further determined the diagnostic value of TACC3 in stage I, II, III, and IV of LUAD (Fig. 3B-3E). The AUCs were 0.930, 0.956, 0.973, and 0.904, respectively. These results indicated that TACC3 could be a potential diagnostic biomarker in LUAD.
High TACC3 expression could be an independent risk factor for OS among LUAD patients
To understand whether TACC3 was an independent risk factor for OS of LUAD patients, univariate and multivariate Cox regression analyses were detected using the R script. In univariate Cox analysis, stage, T and N classification, and TACC3 were independent risk factors (p = 3.07e-11, 2.24e-5, 7.17e-9, and 8.23e-3, respectively, Table 3); while in multivariate Cox analysis, only stage and TACC3 were independent risk factors (p = 2.2e-4, and p = 4.1e-4, respectively). The results indicated that TACC3 expression was an independent risk factor for OS among LUAD patients (HR = 1.43, 95% CI: 1.17–1.7, p < 0.001, Fig. 4).
Table 3
Univariate and multivariate analysis of the correlation of TACC3 expression with OS among LUAD patients.
Parameter | Univariate analysis | | Multivariate analysis |
HR | 95% CI | p-value | | HR | 95% CI | p-value |
Age | 1.01 | 1.00-1.03 | 0.15 | | | | |
Gender | 1.08 | 0.79–1.49 | 0.62 | | | | |
Stage | 1.65 | 1.43–1.92 | 3.07e-11**** | | 1.51 | 1.21–1.87 | 2.2e-4*** |
T classification | 1.53 | 1.26–1.87 | 2.24e-5**** | | 1.16 | 0.94–1.44 | 0.15 |
N classification | 1.70 | 1.42–2.03 | 7.17e-9**** | | 1.14 | 0.90–1.46 | 0.28 |
TACC3 | 1.02 | 1.01–1.04 | 0.00823** | | 1.43 | 1.17–1.70 | 4.1e-4*** |
HR, hard ratio; CI, confidence interval. **values indicate p < 0.01, *** values indicate p < 0.001, ****values indicate p < 0.0001 |
High Expression Of Tacc3 Mrna In Luad Fresh Tissues
To confirm the TACC3 mRNA expression in LUAD, we finally performed Real-Time PCR in 6 pair of matched LUAD tissues and their adjacent noncancerous tissues. As shown in Fig. 6, the expression of TACC3 mRNA was upregulated in LUAD cancer tissues, compared with that in the corresponding noncancerous tissues (p = 0.0052).